Video Interview: Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer, Regulus Therapeutics Inc. [RGLS]

Video Interview: Kleanthis G. Xanthopoulos, Ph.D., President and Chief
Executive Officer, Regulus Therapeutics Inc. [RGLS]

NASDAQ CEO Signature Series Broadcasted From the NASDAQ MarketSite

NEW YORK, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Veteran business journalist Carmen
Roberts joins Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive
Officer, Regulus Therapeutics Inc. to discuss the company's industry,
strategy, financials and positioning. Regulus successfully completed its
Initial Public Offering in October 2012 and is listed on The NASDAQ Global
Market under the symbol "RGLS."

Click here to view video:

http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=56638&k=B32A0694A5DD3FA3CACBC5414EC65AAC

Kleanthis G. Xanthopoulos, Ph.D.

Regulus Therapeutics Inc. [RGLS]

President and Chief Executive Officer and member of the Board of Directors

Kleanthis G. Xanthopoulos, Ph.D., Regulus' President and Chief Executive
Officer, is an entrepreneur who has been involved in founding several
companies. He joined Regulus around the company's formation in 2007.Prior to
joining Regulus, he was a managing director of Enterprise Partners Venture
Capital. Dr. Xanthopoulos co-founded and served as President and Chief
Executive Officer of Anadys Pharmaceuticals, Inc.from its inception in 2000 to
2006, and remained a Director until its acquisition by Roche in 2011. He was
Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from
1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a
Section Head of the National Human Genome Research Institute from 1995 to
1997. Previously, he was an Associate Professor at the Karolinska Institute,
Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The
Rockefeller University, New York. An Onassis Foundation scholar, Dr.
Xanthopoulos received his B.Sc. in Biology with honors from Aristotle
University of Thessaloniki, Greece, and received both his M.Sc. in
Microbiology and Ph.D. in Molecular Biology from the University of Stockholm,
Sweden. Dr. Xanthopoulos is a member of the board of directors of the
Biotechnology Industry Organization (BIO), Apricus Biosciences (NASDAQ: APRI),
Sente Inc., and a member of the board of BIOCOM, Southern California's life
science industry association.

Regulus Therapeutics [RGLS]:

Regulus Therapeutics Inc. (Nasdaq:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting microRNAs.
Regulus is leveraging a mature therapeutic platform based on technology that
has been developed over 20 years. Regulus works with a broad network of
academic collaborators and leverages the oligonucleotide drug discovery and
development expertise of its founding companies, Alnylam Pharmaceuticals
(Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS). Regulus is advancing
microRNA therapeutics toward clinical development in several areas, including
oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed
strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a
research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

For more information on the opportunity to have your CEO discuss your company,
please call NASDAQ CEO Signature Series, 978/461-3141.

The NASDAQ CEO Signature Series logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4839

NASDAQ CEO Signature Series Logo